Results 161 to 170 of about 120,218 (287)

Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer. [PDF]

Front Immunol
Li DM, Pei KG, Yu XZ, Qie MR, Zhong L, Song L.   +5 more
europepmc   +1 more source

Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents [PDF]

, 2017
Abraham, Christopher, Acharya, Sahaja, Chicoine, Michael, Dowling, Joshua, Dunn, Gavin, Huang, Jiayi, Keller, Jesse, Leuthardt, Eric, Mahmood, Mustafaa, Mullen, Daniel, Perkins, Stephanie M, Rich, Keith, Robinson, Clifford G, Tsien, Christina I, Yang, Deshan   +14 more
core   +2 more sources

Prognostic Value of the C‐PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted.
Yi Zhou, Li‐Hua Yang, Jing Tang, Yuan‐Ming Li, Ping Zhao, Zan Li   +5 more
wiley   +1 more source

CTLA-4 blockade shifts the B cell repertoire toward autoimmunity. [PDF]

J Clin Invest
Çakan E, Wang M, Dai Y, Mirouse A, Villanueva-Pachas CR, Bouis D, Boeckers JM, Gera R, Yraita S, Clapp L, Perdigoto AL, Delmotte FR, Massad C, Bacchiocchi A, Ring AM, Kluger Y, Kluger HM, Herold KC, Meffre E.   +18 more
europepmc   +1 more source

Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

Medicine Bulletin, EarlyView.
ABSTRACT Colorectal cancer (CRC) presents significant therapeutic challenges because of chemoresistance, systemic toxicity, and the complexity of the tumor microenvironment (TME). Nanodrug delivery systems (NDDS) have emerged as versatile platforms capable of overcoming these limitations by enhancing tumor accumulation, improving pharmacokinetics, and ...
Qiurong Wei, Yunli Xu, Tianjiao Zhang, Shuyu Xu, Haonan Wang, Yuan Wang, Xinxin Xie, Xiaolong Liang   +7 more
wiley   +1 more source

Investigation of the CTLA-4-CD28 Axis in Oral Squamous Cell Carcinoma. [PDF]

J Clin Med
Feldmeier F, Weber M, Pacelli F, Vogl C, Glajzer J, Trumet L, Buchbender M, Geppert C, Kesting M, Ries J.   +9 more
europepmc   +1 more source

MONOCLONAL ANTIBODIES AGAINST CTLA-4 AND PD-L1 RECEPTORS OF THE CATTLE IMMUNE SYSTEM

S. N. Borovikov, Laura Tokhtarova, Kanatbek Mukantayev, Alfiya Syzdykova   +3 more
openalex   +2 more sources

CTLA‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations [PDF]

, 2015
Luis H. Camacho
openalex   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

CTLA-4 haploinsufficiency presenting with chronic myeloid leukemia, bullous pemphigoid, and PLA2R-positive membranous nephropathy: a case report. [PDF]

Allergy Asthma Clin Immunol
Deeb N, Deeb S, Ahmed FS, Amro YMY, Altell A, Khalili A.   +5 more
europepmc   +1 more source